Corporate Offices

Corporate 2600 Stemmons Freeway,

Suite 176
Fact Sheet Dallas, TX 75207-2107
Tel: (214) 905-5100
Fax: (214) 905-5101
OTC: ACCP http://www.accesspharma.com

Nanotechnology Meets Biotechnology

Company Overview
Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical company focused on the development
and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access
has one approved product, two products in Phase 2 development, and five preclinical development programs. The
Access
Company’sPharmaceuticals,
approved product Inc. (ACCP.OB)
is MuGard™ is an
foremerging pharmaceutical
the management of oral company
mucositis focused
(a common on theanddevelopment and
debilitating side
commercialization
effect of many cancer of proprietary products
therapies) for themarketing
for which treatmentauthorization
and supportivehas care of cancer
been allowedpatients.
by theThe Company’s
FDA. Access’
products
ProLindac include MuGard™ for the
TM, a polymer-linked management
platinum cancerofdrugoral is
mucositis
in Phase (a common
2 clinicaland debilitating
testing in cancerside patients,
effect of many
as is
cancer therapies) for which marketing authorization has been allowed
Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor by the FDA, and ProLindac TM, a polymer-
and a
linked platinumagent.
differentiating cancerThe drug in Phase preclinical
Company’s II clinical testing of cancer
development patients.
programs The Company
include Angiolix, aalso has advanced
humanized drug
monoclonal
delivery technologies including Cobalamin™-mediated targeted delivery and oral drug
antibody which acts as an anti-angiogenesis factor and is potentially targeted to a number tumor types, including delivery.
breast and ovarian; Prodrax, a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill
MuGard™
• tumor cells; Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance,
In the
and area
oral of supportive
insulin, which utilizescare the
for company’s
cancer patients, Access
Cobalamin has drug
TM oral received marketing
delivery allowance for MuGard™ in the
technology.
United States from the Food and Drug Administration. MuGard™ is indicated for the management of mucositis
• MuGard™
which is an ulceration of the oral cavity. Mucositis is a common and debilitating side effect of many cancer
In the area of
treatments. The supportive care for
addressable cancer patients,
worldwide market for Access has received
mucositis marketing
is estimated to be inallowance
excess offor$1MuGard™ in the
billion annually.
United States
MuGard™ provides a from the Food and Drug Administration.
protective coating to the mucosal surfaces in the mouth. A clinical study has shown
MuGard™
MuGard™ toisbeindicatedeffective for the management
in lowering the incidence of and
mucositis
severity of mucositis.
which is an ulceration of the oral cavity. Mucositis is a
common and debilitating side effect of many cancer
• ProLindac™
treatments.
The company’s The lead
addressable worldwideProLindac
drug candidate, market for
TM, mucositis
is currently in a Phase II trial In Europe in ovarian cancer
is estimated to be in excess of $1 billion annually.
patients. ProLindac™ applies the principles of nanoparticulate MuGard™ prodrugs to enhance the delivery of a platinum
provides a protective
drug to tumors. coating tomodels
In preclinical the mucosal surfaces
ProLindac™ in thenormal tissue from the cytotoxic platinum while in
protects
mouth.
circulation and enhances uptake of drug to tumors, whereinthe platinum is released by virtue of a pH-sensitive
A clinical study has shown MuGard™ to be effective
lowering the incidence and
linker. Platinum-based drugs severity of mucositis.
are among the largest classes of chemotherapeutic compounds. The drug used in
ProLindac™ is DACH platinum, which is also the active moiety of oxaliplatin (Eloxatin; Sanofi – Aventis), a drug for
• ProLindac™
cancer patients which has annual sales of $2+ billion worldwide.
The company’s lead drug candidate, ProLindacTM, is currently
in a Phase 2 trial In Europe in ovarian cancer patients.
• Phenylbutyrate
ProLindac™
The company’s applies
lead drugthe candidate,
principles of nanoparticulate
ProLindac prodrugs
TM, is currently to enhance
in a Phase theEurope
II trial In delivery of a platinum
in ovarian cancer drug to
tumors. In preclinical models ProLindac™ protects normal tissue from the
patients. ProLindac™ applies the principles of nanoparticulate prodrugs to enhance the delivery of a platinum cytotoxic platinum while in circulation
drug to
and enhances uptake of drug to tumors, where the platinum is released
tumors. In preclinical models ProLindac™ protects normal tissue from the cytotoxic platinum while in circulation by virtue of a pH-sensitive linker.
and
Platinum-based
enhances uptake of drug drugsto are among
tumors, where thethelargest
platinumclasses of chemotherapeutic
is released compounds.
by virtue of a pH-sensitive The
linker. drug used in
Platinum-based
drugsProLindac™
are amongisthe DACH platinum,
largest classeswhich is also the activecompounds.
of chemotherapeutic moiety of oxaliplatin
The drug used(Eloxatin; Sanofi–Aventis),
in ProLindac™ is DACH a plati-
drug for
num, cancer
whichpatients
is also the which
activehasmoiety
annualofsales of $2+(Eloxatin;
oxaliplatin billion worldwide.
Sanofi – Aventis), a drug for cancer patients which has
annual sales of $2+ billion worldwide
• Cobalamin™ - Coated Nanoparticles
The company also has Cobalamin™ technologies in early-stage development. These technologies are based upon
the use of Cobalamin™–coated nanoparticles, for enhanced targeting of drugs to sites of disease (utilizing the
increased demand for cobalamin that occurs at disease sites, such as cancer). The company also has extensive
intellectual property surrounding the use of this technology for oral drug delivery including oral delivery of insulin.
While oral delivery is by far the preferred route of administration for most drugs, this route is not available to many
existing and/or promising therapeutic compounds because of their physical and chemical properties.
Cobalamin™-coated nanoparticles provide an opportunity for oral delivery of such compounds by utilizing the
body’s natural uptake mechanisms.
February, 2008
 Select Financial Data:
Share Price (2/1/08): $2.80 52-Week Price Range: $2.10-10.66
Shares Outstanding: 17.3 million (includes cs and ps) Market Cap: $48 million

NanoPolymer Platform Technology

Access leverages its proprietary NanoPolymer technology platforms to generate NCEs (new chemical entities) with enhanced drug
effectiveness while decreasing side effects. Nanoparticulate delivery systems can be used to (1) enhance drug absorption,
(2) facilitate sustained targeted delivery, (3) enable oral bioavailability of previously injectable drugs, and (4) mediate side effects.

Recent Company Announcements

• Jan 29, 2008: Access Pharmaceuticals Announces $2.7 Million New Equity
• Jan 14, 2008: Access Licenses MuGard™ to RHEI Pharmaceuticals, a Leading
Specialty Pharmaceutical Company for Distribution in China
and Certain Other Southeast Asian Countries
• Jan 07, 2008: Access Pharmaceuticals Closes Acquisition of Somanta
Pharmaceuticals
Investment Highlights
• Focus on Oncology
Access’ Product Pipeline Chart
• MuGard™ market allowance
received for potential $1 billion
cancer supportive care market
MuGardTM • ProLindacTM has a positive pro-
ProLindacTM file compared to oxaliplatin, a
Ovarian Cancer $2+ billion product
Colorectal/Other • Experienced management team
Oral Insulin/hGH • Product portfolio breadth
Angiolix • Strong IP position
Prodrax
• Numerous strategies to create
Alchemix shareholder value
Phenylbutyrate • Multiple product opportunities
Glioblastoma Partnered
• Broad technology base

For more Information:

Management Team
Investor Relations:
Jeffrey B. Davis, Chairman and Chief Executive Officer Donald C. Weinberger
SCO Financial Group LLC Wolfe Axelrod Weinberger LLC
Esteban Cvitkovic, M.D., Vice Chairman (Europe), (212) 370-
370-4500
Senior Director, Clinical Oncology R&D
Founder, Cvitkovic & Associates Consultants (now owned by AAIOncology) Michael Wachs, CEOcast, Inc.
(212) 732-
732-4300
David P. Nowotnik, Ph.D., Senior Vice President R&D This fact sheet includes historical information and
Sr. Dir. Prod Dev, Guilford ¤ Bristol-Myers Squibb ¤ Amersham International forward-looking actions that Access anticipates,
based on certain assumptions. Actual results could
Phillip Wise, V.P. Business Development & Strategy be different from projections, and Access assumes
VP, Com and Bus Dev & CFO, Enhance Pharmaceuticals ¤ Glaxo Wellcome no obligation to update this information.

Stephen B. Thompson, Vice President, CFO The risks associated with the Company are detailed
in the Company’s Annual Report on Form 10-K for
Controller, Robert E. Woolley Inc. ¤ OKC Limited Partnership ¤ Sante Fe the year ended December 31, 2006 and other
reports filed by the Company with the Securities